Uncategorized
Intravitreal dexamethasone sustains improvements in patients with DME
Retinal structure improvements were sustained over 3 years in patients with diabetic macular edema in whom dexamethasone intravitreal implants were administered at intervals of 6 months or more, according to an analysis.Investigators pooled data from two completed phase 3 trials. The MEAD trials were multicenter, masked, randomized studies that assessed the safety and efficacy of Ozurdex (dexamethasone intravitreal implant, Allergan) monotherapy in patients with DME.